GlassScriptPhysician profile
Rebeca Sandoval
NPI 1023242120
$4,371.77
in general payments reported to CMS, 2019-2025
37 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $124 · 2021: $59.81 · 2022: $24.06 · 2023: $799 · 2024: $1,059 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,603 · Travel and Lodging: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,603.17 |
| Travel and Lodging | $633.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $684.39 | 2025 | |
| Astellas Pharma US INC | $562.86 | 2023-2025 | Veozah |
| Abbvie INC. | $325.51 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $301.37 | 2019-2025 | Aptima, Fetal Fibronectin Enzyme Immunoassay, Acessa Provu System |
| Intuitive Surgical, INC. | $276.53 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $235.31 | 2023-2024 | Myfembree |
| Daiichi Sankyo INC. | $191.87 | 2023-2025 | Injectafer |
| Mayne Pharma Commercial LLC | $175.87 | 2023-2025 | |
| Biogen, INC. | $145.18 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $141.81 | 2020-2025 | Slynd |
| Aspira Women'S Health INC | $136.86 | 2023-2024 | Ova1 |
| Evofem Biosciences, INC. | $134.02 | 2024-2025 | Solosec, Phexx, Phexxi |
| Pfizer INC. | $93.14 | 2024 | |
| Organon LLC | $88.98 | 2022-2024 | Nexplanon |
| Roche Diagnostics Corporation | $86.73 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $83.38 | 2019 | |
| Millicent US INC | $81.65 | 2025 | Intrarosa, Femlyv, Femring |
| Ethicon US, LLC | $76.62 | 2019-2023 | Vistaseal, Surgicel Nu-Knit |
| Bayer Healthcare Pharmaceuticals INC. | $70.14 | 2019-2024 | |
| Therapeuticsmd, INC. | $52.82 | 2019-2020 | |
| Coopersurgical, INC. | $44.89 | 2019-2023 | Paragard T 380a |
| Myovant Sciences INC. | $43.54 | 2021 | |
| Amag Pharmaceuticals, INC. | $38.23 | 2019 | |
| Exact Sciences Corporation | $36.57 | 2023-2025 | Cologuard Collection Kit |
| Duchesnay USA Incorporated | $30.38 | 2019 | |
| Lilly USA, LLC | $29.46 | 2025 | Zepbound, Mounjaro |
| Applied Medical Resources Corporation | $28.95 | 2023 | |
| Avion Pharmaceuticals | $27.79 | 2019 | |
| Teleflex LLC | $21.99 | 2025 | Quikclot |
| Merck Sharp & Dohme LLC | $19.97 | 2019 | |
| Conmed Corporation | $19.80 | 2025 | Airseal |
| Mission Pharmacal Company | $16.81 | 2019 | |
| Meditrina | $16.24 | 2025 | |
| Novo Nordisk INC | $15.20 | 2023 | Wegovy, Saxenda |
| Cumberland Pharmaceuticals, INC. | $13.36 | 2019 | |
| Minerva Surgical, INC | $12.74 | 2019 | |
| Lupin INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebeca Sandoval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.